IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor
type: MedicalStudy
description: A Phase Ia/Ib First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of IMA401, a Bispecific T Cell Engaging Receptor Molecule (TCER®), as Monotherapy or in Combination With Checkpoint Inhibitor in Patients With Recurrent and/or Refractory Solid Tumors.
status: ACTIVE_NOT_RECRUITING
study design: INTERVENTIONAL
phase: PHASE1
start date: 2022-05-19
end date: 2029-12
license: https://creativecommons.org/publicdomain/zero/1.0/
source: https://clinicaltrials.gov/study/NCT05359445
source organization: US National Library of Medicine
publisher: AI Analytics
sponsor: Immatics Biotechnologies GmbH
study subject: Refractory Cancer
study subject: Recurrent Cancer
study subject: Solid Tumor, Adult
study subject: Cancer
keywords: PHASE1
keywords: INTERVENTIONAL
keywords: ACTIVE_NOT_RECRUITING
keywords: Refractory Cancer
keywords: Recurrent Cancer
keywords: Solid Tumor, Adult
keywords: Cancer

AI Analytics
type: Organization